The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
Astellas Pharma presented new results from cohort 9 of the EV-202 trial at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany, from 17 to 21 October. Conducted in ...
First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results